Gyre Therapeutics, Inc.
GYRE
$8.60
-$0.21-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -108.81% | -68.14% | -53.16% | 107.46% | -2,640.39% |
| Total Depreciation and Amortization | 3.74% | 90.76% | -44.00% | 37.99% | 52.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.87% | 77.57% | -47.31% | -97.89% | 2,219.33% |
| Change in Net Operating Assets | -124.81% | 83.52% | -46.17% | -165.67% | 1,830.32% |
| Cash from Operations | -259.79% | 131.42% | -290.46% | -14.17% | -55.68% |
| Capital Expenditure | 109.38% | 52.40% | -530.30% | 90.06% | -17.73% |
| Sale of Property, Plant, and Equipment | 2,860.00% | -102.29% | 336.00% | -70.06% | -53.99% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.67% | 75.99% | 0.06% | -402.43% | 63.02% |
| Cash from Investing | 16.05% | 71.15% | -14.58% | -639.21% | 124.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 255.88% | 36.00% | -58.21% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -634.00% | 57.98% | -- | -- | -- |
| Cash from Financing | 197.53% | 107.69% | -76.29% | -73.68% | -- |
| Foreign Exchange rate Adjustments | -340.57% | 235.90% | -69.57% | -119.91% | 35.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,654.55% | 98.31% | -267.56% | -150.12% | 215.77% |